Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Vaccine
|
October 21, 2018
Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability
Lan Zhang, Eberhard Durr, Jennifer D Galli, et al.
Plos One
|
October 21, 2016
Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein
Jessica A Flynn, Eberhard Durr, Ryan Swoyer, et al.
Nature Medicine
|
August 22, 2006
TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis
Carolyn G King, Takashi Kobayashi, Pedro J Cejas, et al.
Molecular Therapy. Nucleic Acids
|
April 10, 2025
Inhibition of IFNAR-JAK signaling enhances tolerability and transgene expression of systemic non-viral DNA delivery
Sujata Senapati, Thais B Bertolini, Michael A Minnier, et al.
Vaccine
|
June 9, 2022
Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates
Jessica A Flynn, Teresa Weber, Pedro J Cejas, et al.
Vaccine
|
September 30, 2023
Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults
Jesse Nussbaum, Xin Cao, Radha A Railkar, et al.
Immunity
|
June 25, 2013
Dendritic cell expression of the signaling molecule TRAF6 is critical for gut microbiota-dependent immune tolerance
Daehee Han, Matthew C Walsh, Pedro J Cejas, et al.
Cell Host & Microbe
|
December 8, 2021
Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates
Tomer Zohar, Jeff C Hsiao, Nickita Mehta, et al.
JCI Insight
|
March 23, 2026
DNA delivered by lipid nanoparticles induces CD8+ T cell-dependent antitumor responses and enhances anti-PD-L1 therapy
Seoyun Yum, Alba Rodríguez-Garcia, Joan Castellsagué, et al.
Nature Communications
|
September 14, 2019
A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein
Aimin Tang, Zhifeng Chen, Kara S Cox, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Vaccine
|
October 21, 2018
Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability
Lan Zhang, Eberhard Durr, Jennifer D Galli, et al.
Plos One
|
October 21, 2016
Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein
Jessica A Flynn, Eberhard Durr, Ryan Swoyer, et al.
Nature Medicine
|
August 22, 2006
TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis
Carolyn G King, Takashi Kobayashi, Pedro J Cejas, et al.
Molecular Therapy. Nucleic Acids
|
April 10, 2025
Inhibition of IFNAR-JAK signaling enhances tolerability and transgene expression of systemic non-viral DNA delivery
Sujata Senapati, Thais B Bertolini, Michael A Minnier, et al.
Vaccine
|
June 9, 2022
Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates
Jessica A Flynn, Teresa Weber, Pedro J Cejas, et al.
Vaccine
|
September 30, 2023
Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults
Jesse Nussbaum, Xin Cao, Radha A Railkar, et al.
Immunity
|
June 25, 2013
Dendritic cell expression of the signaling molecule TRAF6 is critical for gut microbiota-dependent immune tolerance
Daehee Han, Matthew C Walsh, Pedro J Cejas, et al.
Cell Host & Microbe
|
December 8, 2021
Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates
Tomer Zohar, Jeff C Hsiao, Nickita Mehta, et al.
JCI Insight
|
March 23, 2026
DNA delivered by lipid nanoparticles induces CD8+ T cell-dependent antitumor responses and enhances anti-PD-L1 therapy
Seoyun Yum, Alba Rodríguez-Garcia, Joan Castellsagué, et al.
Nature Communications
|
September 14, 2019
A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein
Aimin Tang, Zhifeng Chen, Kara S Cox, et al.
Page
of 3